FY2024 Earnings Estimate for Pfizer Issued By Zacks Research

Pfizer Inc. (NYSE:PFE) – Research analysts at Zacks Research raised their FY2024 EPS estimates for Pfizer in a report issued on Monday, November 18th. Zacks Research analyst K. Shah now forecasts that the biopharmaceutical company will post earnings of $2.87 per share for the year, up from their previous estimate of $2.57. The consensus estimate for Pfizer’s current full-year earnings is $2.95 per share. Zacks Research also issued estimates for Pfizer’s Q2 2026 earnings at $0.63 EPS, Q3 2026 earnings at $0.78 EPS and FY2026 earnings at $2.94 EPS.

Other equities analysts have also issued research reports about the stock. Wolfe Research began coverage on shares of Pfizer in a report on Friday, November 15th. They set an “underperform” rating and a $25.00 target price on the stock. Citigroup started coverage on Pfizer in a report on Friday, October 25th. They issued a “neutral” rating and a $30.00 price objective on the stock. Daiwa America upgraded Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th. StockNews.com lowered Pfizer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday. Finally, Barclays upped their price target on shares of Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. One analyst has rated the stock with a sell rating, eight have issued a hold rating, six have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $32.92.

Pfizer Stock Up 0.5 %

Shares of NYSE PFE opened at $25.06 on Wednesday. The stock has a market capitalization of $142.03 billion, a P/E ratio of 33.87, a PEG ratio of 0.80 and a beta of 0.67. Pfizer has a one year low of $24.48 and a one year high of $31.54. The firm’s 50 day simple moving average is $28.28 and its two-hundred day simple moving average is $28.58. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.64 by $0.42. The firm had revenue of $17.70 billion during the quarter, compared to analysts’ expectations of $14.92 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The company’s revenue for the quarter was up 31.2% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.17) EPS.

Institutional Trading of Pfizer

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Olistico Wealth LLC purchased a new stake in Pfizer in the second quarter worth approximately $25,000. MFA Wealth Advisors LLC bought a new stake in shares of Pfizer during the second quarter valued at approximately $29,000. Gladius Capital Management LP boosted its position in shares of Pfizer by 102.8% during the third quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 38,015 shares during the last quarter. Quarry LP purchased a new position in Pfizer during the second quarter valued at $31,000. Finally, Financial Connections Group Inc. bought a new stake in Pfizer in the 2nd quarter valued at $34,000. 68.36% of the stock is currently owned by institutional investors.

Insider Activity at Pfizer

In related news, Director Scott Gottlieb bought 1,000 shares of the company’s stock in a transaction on Wednesday, October 30th. The shares were acquired at an average cost of $28.24 per share, with a total value of $28,240.00. Following the completion of the acquisition, the director now owns 10,000 shares of the company’s stock, valued at $282,400. The trade was a 11.11 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.06% of the stock is currently owned by corporate insiders.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be paid a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.70%. The ex-dividend date is Friday, November 8th. Pfizer’s payout ratio is presently 227.03%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.